Special ReportsAll NewsFDA BriefsOncology IconsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesEvolving Paradigms in OncologyExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPersonalized MedicinePivotal Practice Views with the Oncology BrothersPodcastsSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsEventsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Myeloma
  • Chronic Lymphocytic Leukemia
  • Gynecologic Cancers
  • Genomic Testing
  • Melanoma
  • Genitourinary Cancers
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Age-Related Characteristics Impact Outcomes in AML

May 27, 2021
Video

Rajneesh Nath, MD, discusses outcomes for older patients with acute myeloid leukemia.

Rajneesh Nath, MD, a medical oncologist and the section chief of Cellular Therapy/Stem Cell Transplant & Leukemia at Banner MD Anderson Cancer Center, discusses outcomes for older patients with acute myeloid leukemia.

According to Nath, AML is a disease of the elderly, with the median age at diagnosis being 68 years. The median age of patients at diagnosis also continues to steadily rise. Based on results of registry trials, it is known that as the patient population gets older, they tend to have poorer outcome compared to younger patients. The 1 to 2-year survival rate among these patients is10% or less.

Most patients will first receive induction chemotherapy, and those that go into complete remission will receive allogenic stem cell transplantation. According to Nath, many oncologists used to have an upper age limit as to whether they would consider a patient for transplant. However, that is no longer the case after several studies found that older patients tend to do just as well as younger patients after transplant.

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Related Content

FDA Grants Priority Review to NDA of Ziftomenib in NPM1-Mutant AML

FDA Grants Priority Review to NDA of Ziftomenib in NPM1-Mutant AML

Jordyn Sava
June 3rd 2025
Article

If approved, ziftomenib could be the first FDA-approved Menin inhibitor for relapsed/refractory acute myeloid leukemia with an NPM1 mutation.

Read More


Phase 1/2 Trial of Oral Zelenirstat Launches in Relapsed/Refractory AML

Phase 1/2 Trial of Oral Zelenirstat Launches in Relapsed/Refractory AML

Jonah Feldman
March 19th 2025
Article

The first patient in a trial received oral zelenirstat, a N-myristoyltransferase inhibitor, to determine its safety and tolerability in relapsed/refractory AML.

Read More


Disparities in AML Highlight Need for Tailored Strategies for Elderly Patients

Disparities in AML Highlight Need for Tailored Strategies for Elderly Patients

Jordyn Sava
January 27th 2025
Article

Patients with AML aged 80 years and older face poor survival despite treatment advances, highlighting the need for improved, equitable care strategies and tailored treatment approaches.

Read More


Phase 3 REGAL Trial of Galinpepimut-S in AML Advances Toward Completion

Phase 3 REGAL Trial of Galinpepimut-S in AML Advances Toward Completion

Jordyn Sava
January 24th 2025
Article

The phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia can proceed without modifications, based on findings from the prespecified interim analysis of the study.

Read More


FDA Grants Rare Pediatric Disease Designation to Galinpepimut-S in AML

FDA Grants Rare Pediatric Disease Designation to Galinpepimut-S in AML

Jordyn Sava
October 17th 2024
Article

The FDA granted galinpepimut-S a rare pediatric disease designation for the treatment of pediatric patients with acute myeloid leukemia.

Read More


FDA Clears IND of Novel ADC in AML Treatment

FDA Clears IND of Novel ADC in AML Treatment

Sabrina Serani
October 14th 2024
Article

BL-M11D1, a CD33-binding antibody-drug conjugate, is being evaluated for the treatment of patients with acute myeloid leukemia.

Read More

Related Content

FDA Grants Priority Review to NDA of Ziftomenib in NPM1-Mutant AML

FDA Grants Priority Review to NDA of Ziftomenib in NPM1-Mutant AML

Jordyn Sava
June 3rd 2025
Article

If approved, ziftomenib could be the first FDA-approved Menin inhibitor for relapsed/refractory acute myeloid leukemia with an NPM1 mutation.

Read More


Phase 1/2 Trial of Oral Zelenirstat Launches in Relapsed/Refractory AML

Phase 1/2 Trial of Oral Zelenirstat Launches in Relapsed/Refractory AML

Jonah Feldman
March 19th 2025
Article

The first patient in a trial received oral zelenirstat, a N-myristoyltransferase inhibitor, to determine its safety and tolerability in relapsed/refractory AML.

Read More


Disparities in AML Highlight Need for Tailored Strategies for Elderly Patients

Disparities in AML Highlight Need for Tailored Strategies for Elderly Patients

Jordyn Sava
January 27th 2025
Article

Patients with AML aged 80 years and older face poor survival despite treatment advances, highlighting the need for improved, equitable care strategies and tailored treatment approaches.

Read More


Phase 3 REGAL Trial of Galinpepimut-S in AML Advances Toward Completion

Phase 3 REGAL Trial of Galinpepimut-S in AML Advances Toward Completion

Jordyn Sava
January 24th 2025
Article

The phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia can proceed without modifications, based on findings from the prespecified interim analysis of the study.

Read More


FDA Grants Rare Pediatric Disease Designation to Galinpepimut-S in AML

FDA Grants Rare Pediatric Disease Designation to Galinpepimut-S in AML

Jordyn Sava
October 17th 2024
Article

The FDA granted galinpepimut-S a rare pediatric disease designation for the treatment of pediatric patients with acute myeloid leukemia.

Read More


FDA Clears IND of Novel ADC in AML Treatment

FDA Clears IND of Novel ADC in AML Treatment

Sabrina Serani
October 14th 2024
Article

BL-M11D1, a CD33-binding antibody-drug conjugate, is being evaluated for the treatment of patients with acute myeloid leukemia.

Read More

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Editorial Board
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.